Comparative Pharmacology
Head-to-head clinical analysis: PYOCIDIN versus TIMENTIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PYOCIDIN versus TIMENTIN.
PYOCIDIN vs TIMENTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Pyocidin is a bactericidal antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-tRNA to the mRNA-ribosome complex.
Timentin is a combination of ticarcillin, a penicillin-class antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), and clavulanic acid, a beta-lactamase inhibitor that irreversibly inhibits a wide range of beta-lactamase enzymes, thereby preventing degradation of ticarcillin and extending its spectrum to include beta-lactamase-producing organisms.
5 mg/kg intramuscular or subcutaneous every 24 hours. Max dose 300 mg per injection.
3.1 g (ticarcillin 3 g + clavulanic acid 0.1 g) IV every 4-6 hours; for moderate infections, 3.1 g IV every 6 hours; for severe infections, 3.1 g IV every 4 hours.
None Documented
None Documented
Terminal elimination half-life is 2-3 hours in patients with normal renal function; extends to 12-18 hours in severe renal impairment (CrCl <30 mL/min).
Ticarcillin: ~1.1 hours; clavulanate: ~1.0 hours. Prolonged in renal impairment (CrCl <10 mL/min: ticarcillin half-life ~13 hours).
Primarily renal excretion of unchanged drug (60-70%), with 20-30% biliary excretion and minor fecal elimination (<10%).
Renal: 60-80% ticarcillin and 50-70% clavulanate excreted unchanged in urine via glomerular filtration and tubular secretion. Fecal: minimal.
Category C
Category C
Antibiotic
Antibiotic